Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
Melody B Oncale, Hossein Maymani, Loretta J Nastoupil Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma....
Main Authors: | Oncale MB, Maymani H, Nastoupil LJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-02-01
|
Series: | Blood and Lymphatic Cancer : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/harnessing-the-immune-system-through-programmed-death-1-blockade-in-th-peer-reviewed-article-BLCTT |
Similar Items
-
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
by: Lorenzo Falchi, et al.
Published: (2016-11-01) -
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
by: Elisa Lucchini, et al.
Published: (2021-06-01) -
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
by: Bond DA, et al.
Published: (2017-05-01) -
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
by: Theodoros P. Vassilakopoulos, et al.
Published: (2019-07-01) -
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)